Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs.

Medrano MÁ, Álvarez-Valdés A, Perles J, Lloret-Fillol J, Muñoz-Galván S, Carnero A, Navarro-Ranninger C, Quiroga AG.

Chem Commun (Camb). 2013 May 25;49(42):4806-8. doi: 10.1039/c3cc38416k.

PMID:
23591566
2.

Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs.

Varbanov HP, Valiahdi SM, Kowol CR, Jakupec MA, Galanski M, Keppler BK.

Dalton Trans. 2012 Dec 21;41(47):14404-15. doi: 10.1039/c2dt31366a.

PMID:
22886297
3.

The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity.

Cubo L, Hambley TW, Sanz Miguel PJ, Carnero A, Navarro-Ranninger C, Quiroga AG.

Dalton Trans. 2011 Jan 14;40(2):344-7. doi: 10.1039/c0dt00565g. Epub 2010 Oct 8.

PMID:
20936210
4.

Tetracarboxylatoplatinum(IV) complexes featuring monodentate leaving groups - A rational approach toward exploiting the platinum(IV) prodrug strategy.

Höfer D, Varbanov HP, Legin A, Jakupec MA, Roller A, Galanski M, Keppler BK.

J Inorg Biochem. 2015 Dec;153:259-71. doi: 10.1016/j.jinorgbio.2015.08.018. Epub 2015 Aug 28.

PMID:
26365319
5.

Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.

Xu Z, Wang Z, Yiu SM, Zhu G.

Dalton Trans. 2015 Dec 14;44(46):19918-26. doi: 10.1039/c5dt03101j.

PMID:
26514681
6.

Solution behaviour and biomolecular interactions of two cytotoxic trans-platinum(II) complexes bearing aliphatic amine ligands.

Cubo L, Casini A, Gabbiani C, Mastrobuoni G, Messori L, Jiménez-Barbero J, Navarro-Ranninger C, Quiroga AG.

Chemistry. 2009 Sep 14;15(36):9139-46. doi: 10.1002/chem.200901090.

PMID:
19655350
7.

Influence of (hydroxymethyl)pyridine and pyridine-carboxylic acids, in trans-position to the isopropylamine and amine ligands, on the cytotoxicity of platinum complexes.

Medina RM, Rodríguez J, Quiroga AG, Ramos-Lima FJ, Moneo V, Carnero A, Navarro-Ranninger C, Macazaga MJ.

Chem Biodivers. 2008 Oct;5(10):2090-100. doi: 10.1002/cbdv.200890190.

PMID:
18972499
8.

Diazido mixed-amine platinum(IV) anticancer complexes activatable by visible-light form novel DNA adducts.

Zhao Y, Woods JA, Farrer NJ, Robinson KS, Pracharova J, Kasparkova J, Novakova O, Li H, Salassa L, Pizarro AM, Clarkson GJ, Song L, Brabec V, Sadler PJ.

Chemistry. 2013 Jul 15;19(29):9578-91. doi: 10.1002/chem.201300374. Epub 2013 Jun 3.

9.

Photoactivatable platinum complexes.

Bednarski PJ, Mackay FS, Sadler PJ.

Anticancer Agents Med Chem. 2007 Jan;7(1):75-93. Review.

PMID:
17266506
10.

Studies on the photoactivation of two cytotoxic trans,trans,trans-diazidodiaminodihydroxo-Pt(IV) complexes.

Westendorf AF, Bodtke A, Bednarski PJ.

Dalton Trans. 2011 May 21;40(19):5342-51. doi: 10.1039/c0dt01485k. Epub 2011 Apr 4.

PMID:
21461431
11.

The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs.

Göschl S, Varbanov HP, Theiner S, Jakupec MA, Galanski M, Keppler BK.

J Inorg Biochem. 2016 Jul;160:264-74. doi: 10.1016/j.jinorgbio.2016.03.005. Epub 2016 Mar 17.

PMID:
27055943
12.

Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES).

Hall MD, Daly HL, Zhang JZ, Zhang M, Alderden RA, Pursche D, Foran GJ, Hambley TW.

Metallomics. 2012 Jun;4(6):568-75. doi: 10.1039/c2mt20053h. Epub 2012 May 9.

PMID:
22569908
13.

Influence of amine ligands on the aquation and cytotoxicity of trans-diamine platinum(II) anticancer complexes.

Cubo L, Quiroga AG, Zhang J, Thomas DS, Carnero A, Navarro-Ranninger C, Berners-Price SJ.

Dalton Trans. 2009 May 14;(18):3457-66. doi: 10.1039/b819301k. Epub 2009 Jan 29.

PMID:
19381408
14.

Kinetics and mechanism for reduction of anticancer-active tetrachloroam(m)ine platinum(IV) compounds by glutathione.

Lemma K, Berglund J, Farrell N, Elding LI.

J Biol Inorg Chem. 2000 Jun;5(3):300-6.

PMID:
10907740
15.
16.

New trans-platinum drugs with phosphines and amines as carrier ligands induce apoptosis in tumor cells resistant to cisplatin.

Ramos-Lima FJ, Quiroga AG, García-Serrelde B, Blanco F, Carnero A, Navarro-Ranninger C.

J Med Chem. 2007 May 3;50(9):2194-9. Epub 2007 Apr 4.

PMID:
17407274
17.

Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(IV) anticancer prodrug and model complex: kinetic and mechanistic studies.

Huo S, Shen S, Liu D, Shi T.

J Phys Chem B. 2012 Jun 7;116(22):6522-8. doi: 10.1021/jp302600a. Epub 2012 May 22.

PMID:
22574871
18.

New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes.

Turánek J, Kasná A, Záluská D, Neca J, Kvardová V, Knötigová P, Horváth V, SIndlerová L, Kozubík A, Sova P, Kroutil A, Zák F, Mistr A.

Anticancer Drugs. 2004 Jun;15(5):537-43.

PMID:
15166629
19.

What do we know about the reduction of Pt(IV) pro-drugs?

Wexselblatt E, Gibson D.

J Inorg Biochem. 2012 Dec;117:220-9. doi: 10.1016/j.jinorgbio.2012.06.013. Epub 2012 Jul 2. Review.

PMID:
22877926
20.

Synthesis and characterization of Pt(IV) fluorescein conjugates to investigate Pt(IV) intracellular transformations.

Song Y, Suntharalingam K, Yeung JS, Royzen M, Lippard SJ.

Bioconjug Chem. 2013 Oct 16;24(10):1733-40. doi: 10.1021/bc400281a. Epub 2013 Sep 10.

Supplemental Content

Support Center